Vanessa Bolejack

6.2k total citations
34 papers, 1.7k citations indexed

About

Vanessa Bolejack is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Vanessa Bolejack has authored 34 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Hematology. Recurrent topics in Vanessa Bolejack's work include Multiple Myeloma Research and Treatments (12 papers), Sarcoma Diagnosis and Treatment (11 papers) and Lymphoma Diagnosis and Treatment (5 papers). Vanessa Bolejack is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Sarcoma Diagnosis and Treatment (11 papers) and Lymphoma Diagnosis and Treatment (5 papers). Vanessa Bolejack collaborates with scholars based in United States, Italy and United Kingdom. Vanessa Bolejack's co-authors include Bart Barlogie, John Crowley, Guido Tricot, Maurizio Zangari, Denise K. Reinke, Mauricio Pineda‐Roman, Frits van Rhee, Kristen N. Ganjoo, Robert G. Maki and Klaus Hollmig and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Vanessa Bolejack

34 papers receiving 1.7k citations

Peers

Countries citing papers authored by Vanessa Bolejack

Since Specialization

Citations

This map shows the geographic impact of Vanessa Bolejack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa Bolejack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa Bolejack more than expected).

Fields of papers citing papers by Vanessa Bolejack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa Bolejack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa Bolejack. The network helps show where Vanessa Bolejack may publish in the future.

Co-authorship network of co-authors of Vanessa Bolejack

This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa Bolejack. A scholar is included among the top collaborators of Vanessa Bolejack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa Bolejack. Vanessa Bolejack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results 2022 ·Cancer Medicine ·Steven Attia, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel A. Rushing, Elizabeth T. Loggers, Michael B. Livingston, Jennifer Wright, Sant P. Chawla, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Lara E. Davis, Christopher W. Ryan, Robert G. Maki	30
2	TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC). 2020 ·Journal of Clinical Oncology ·Samuel R. Denmeade, Hao Wang, (unknown), Wei Fu, Ting Wang, Rehab Abdallah, Vanessa Bolejack, Neeraj Agarwal, David C. Smith, Michael T. Schweizer, Mark N. Stein, Vasily J. Assikis, Thomas W. Flaig, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Channing J. Paller, Michael A. Carducci, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis	2
3	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma 2019 ·Journal of Clinical Oncology ·Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant P. Chawla, Mark Agulnik, Michael B. Livingston, Damon R. Reed, (unknown), Daniel A. Rushing, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Steven Attia, Leo Mascarenhas, Robert G. Maki	174
4	Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. 2019 ·Journal of Clinical Oncology ·Melissa Burgess, Vanessa Bolejack, Scott M. Schuetze, Brian Andrew Van Tine, Steven Attia, Richard F. Riedel, James Hu, Lara E. Davis, Scott H. Okuno, Dennis A. Priebat, Sujana Movva, Damon R. Reed, Sandra P. D’Angelo, Alexander J. Lazar, Emily Z. Keung, Denise K. Reinke, Laurence H. Baker, Robert G. Maki, Shreyaskumar Patel, Hussein Tawbi	82
5	Immune classification of soft tissue sarcoma predicts clinical outcome 2019 ·Annals of Oncology ·Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung, (unknown), Cheng‐Ming Sun, Yung‐Ming Jeng, Li-Ping Hsiao, (unknown), Carlo Lucchesi, Maud Toulmonde, Melissa Burgess, Vanessa Bolejack, Denise K. Reinke, (unknown), Christina L. Roland, Jennifer A. Wargo, Antoîne Italiano, Catherine Sautès‐Fridman, Hussein Tawbi, Wolf H. Fridman	2
6	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients 2017 ·Journal of Gastrointestinal Oncology ·Ramesh K. Ramanathan, Glen J. Weiss, Richard G. Posner, N.V. Rajeshkumar, Gayle Jameson, Meraj Aziz, Antje Hoering, Vanessa Bolejack, Anirban Maitra, (unknown), Edward C. Stites, William S. Hlavacek, Zoran Gatalica, Joanne Xiu, Manuel Hidalgo, Daniel D. Von Hoff, Michael T. Barrett	1
7	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. 2017 ·Journal of Clinical Oncology ·Melissa Burgess, Vanessa Bolejack, Brian Andrew Van Tine, Scott M. Schuetze, James Hu, Sandra P. D’Angelo, Steven Attia, Dennis A. Priebat, Scott H. Okuno, Richard F. Riedel, Lara E. Davis, Sujana Movva, Damon R. Reed, Lisa H. Butterfield, Jason Roszik, Denise K. Reinke, Laurence H. Baker, Robert G. Maki, Shreyaskumar Patel, Hussein Tawbi	31
8	Response to Early Treatment Evaluated with ¹⁸F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor 2016 ·Journal of Nuclear Medicine ·Joo Hyun O, Brandon Luber, Jeffrey P. Leal, Hao Wang, Vanessa Bolejack, Scott M. Schuetze, Lawrence H. Schwartz, Lee J. Helman, Denise K. Reinke, Laurence H. Baker, Richard L. Wahl	18
9	Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) 2014 ·Cancer Chemotherapy and Pharmacology ·Tomislav Dragovich, Daniel A. Laheru, Farshid Dayyani, Vanessa Bolejack, Lee Smith, (unknown), Howard A. Burris, Peter J. Rosen, Manuel Hidalgo, Paul S. Ritch, Amanda F. Baker, Natarajan Raghunand, John Crowley, Daniel D. Von Hoff	56
10	A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study 2014 ·Cancer ·Alberto S. Pappo, Gilles Vassal, John J. Crowley, Vanessa Bolejack, Pancras C.W. Hogendoorn, Rashmi Chugh, Marc Ladanyi, Joseph F. Grippo, (unknown), Arthur P. Staddon, Sant P. Chawla, Robert G. Maki, Dejka M. Araujo, Birgit Geoerger, Kristen N. Ganjoo, Neyssa Marina, Jean‐Yves Blay, Scott M. Schuetze, Warren Chow, Lee J. Helman	148
11	Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid 2010 ·American Journal of Hematology ·James R. Berenson, Ori Yellin, John Crowley, Adel Makary, Donald Gravenor, Hank H. Yang, (unknown), Ian W. Flinn, Harry Staszewski, (unknown), (unknown), Charles M. Farber, Neil Morganstein, Vanessa Bolejack, Youram Nassir, James Hilger, (unknown), (unknown), Regina A. Swift	15
12	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma 2010 ·Journal of Clinical Oncology ·Heinz Ludwig, Vanessa Bolejack, John Crowley, Joan Bladé, Jesús F. San Miguel, Robert A. Kyle, S. Vincent Rajkumar, Kazuyuki Shimizu, Ingemar Turesson, Jan Westin, Pieter Sonneveld, Michèle Cavo, Mario Boccadoro, Antonio Palumbo, Patrizia Tosi, Jean‐Luc Harousseau, Michel Attal, Bart Barlogie, A. Keith Stewart, Brian G.M. Durie	114
13	Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) 2010 ·Blood ·Jeffrey A. Zonder, John Crowley, Mohamad A. Hussein, Vanessa Bolejack, Dennis F. Moore, Brock Whittenberger, Muneer H. Abidi, Brian G.M. Durie, Bart Barlogie	149
14	High‐dose melphalan‐based autotransplants for multiple myeloma 2008 ·Cancer ·Mauricio Pineda‐Roman, Bart Barlogie, Elias Anaissie, Maurizio Zangari, Vanessa Bolejack, Frits van Rhee, Guido Tricot, John Crowley	11
15	Standardized evaluation of regional and institutional breast cancer outcomes 2008 ·The American Journal of Surgery ·J. David Beatty, (unknown), Mary Atwood, (unknown), Vanessa Bolejack	3
16	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 2007 ·British Journal of Haematology ·Bart Barlogie, Elias Anaissie, Frits van Rhee, Jeffrey Haessler, Klaus Hollmig, Mauricio Pineda‐Roman, Michele Cottler‐Fox, Abid Mohiuddin, Yazan Alsayed, Guido Tricot, Vanessa Bolejack, Maurizio Zangari, Joshua Epstein, Nathan Petty, (unknown), Bonnie Jenkins, (unknown), Ellen Sullivan, John Crowley, John D. Shaughnessy	245
17	Occupational Exposure to Solvents and the Risk of Lymphomas 2006 ·Epidemiology ·Lucia Miligi, Adele Seniori Costantini, Alessandra Benvenuti, David Kriebel, Vanessa Bolejack, Rosario Tumino, Valerio Ramazzotti, Stefania Rodella, Emanuele Stagnaro, Paolo Crosignani, Dino Amadori, Dario Mirabelli, (unknown), (unknown), (unknown), Luciano Romeo, Giuseppe Miceli, (unknown), (unknown), Paolo Vineis	61
18	Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma 2006 ·Clinical Lymphoma & Myeloma ·Bart Barlogie, Maurizio Zangari, Vanessa Bolejack, Klaus Hollmig, Elias Anaissie, Frits van Rhee, Mauricio Pineda‐Roman, Abid Mohiuddin, John Crowley, Guido Tricot	10
19	Immunotoxic effects of chemicals: A matrix for occupational and environmental epidemiological studies 2006 ·American Journal of Industrial Medicine ·(unknown), Adele Seniori Costantini, Vanessa Bolejack, Lucia Miligi, Paolo Vineis, Henk Van Loveren	45
20	Non‐Hodgkin's lymphoma, leukemia, and exposures in agriculture: Results from the Italian multicenter case‐control study 2003 ·American Journal of Industrial Medicine ·Lucia Miligi, Adele Seniori Costantini, Vanessa Bolejack, (unknown), Alessandra Benvenuti, Oriana Nanni, Valerio Ramazzotti, Rosario Tumino, Emanuele Stagnaro, Stefania Rodella, Arabella Fontana, Carla Vindigni, Paolo Vineis	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact